+473.9%
SE vs MRNA
+840.0%
-366.1%
-90.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -3.1% | -3.9% | +0.9% | -2.6% |
| 7D | -9.6% | -17.6% | +8.0% | -7.6% |
| 30D | -25.9% | -5.1% | -20.8% | -25.8% |
| 3M | -41.9% | +220.8% | -262.7% | -54.3% |
| 6M | -21.3% | +321.7% | -343.0% | -41.7% |
| YTD | -45.6% | +601.3% | -646.8% | -63.9% |
| 1Y | -52.4% | +735.2% | -787.6% | -69.6% |
| 3Y | +84.8% | +170.5% | -85.7% | +35.7% |
| 5Y | -77.9% | -14.6% | -63.3% | -80.6% |
| All | +473.9% | +840.0% | -366.1% | +337.6% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling